Efficacy and Safety of Mirogabalin Therapy for Paclitaxel-Induced Peripheral Neuropathy (MICHEL Study): A Pilot Study
Although mirogabalin was not wholly effective for CIPN caused by paclitaxel treatment in breast cancer patients, the satisfaction survey suggests some patient-perceived benefits which cannot be detected by conventional evaluation methods.
Authors
- Tomohei Matsuo (ORCID: https://orcid.org/0000-0001-5630-5100)
- Mai Okazaki
- Akiko Iguchi‐Manaka (ORCID: https://orcid.org/0000-0002-0338-130X)
- Hiroko Bando (ORCID: https://orcid.org/0000-0002-7361-3647)
- Aya Sawa
- Riko Sato (ORCID: https://orcid.org/0000-0002-2227-8332)
- Sachie Hashimoto (ORCID: https://orcid.org/0000-0001-5973-9051)
- Hisato Hara (ORCID: https://orcid.org/0000-0002-2764-0353)
Institutions
- University of Tsukuba (JP)
- University of Tsukuba Hospital (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1159/000543798
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00